Performance and patient acceptance of a commercially available beverage as compared to an oral glucose solution for oral glucose tolerance tests in cystic fibrosis (CF) patients who are screened for CF-related diabetes.

Recruiting

• Conditions: CF; Cystic fibrosis; 10038686; 10018424

• Registration Number: NL-OMON51410
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 20

Inclusion Criteria

- Age * 18
- Diagnosed with CF
- One of the following: Diagnosed with CFRD or IGT based on a raise fasting
glucose level or OGTT. Or; pancreatic insufficiency, without CFRD

Exclusion Criteria

- Age < 18
- Active infection or inflammation
- Use of medication known to affect insulin secretion or insulin resistance,
other than short-acting insulin.
- No informed consent

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Serum glucose levels at 120 minutes after ingestion of either the standard<br /><br>glucose solution or the sportsdrink. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- Serum glucose levels at 30, 60 and 90 minutes after ingestion of either the<br /><br>standard glucose solution or AA drink.<br /><br>- Patient satisfaction for the ingested test product using a VAS on the<br /><br>following points: overall satisfaction (very dissatisfied * very satisfied),<br /><br>taste (really bad * really good), ease of drinking (very difficult * very easy)<br /><br>and side effects after drinking (e.g. nauseousness, stomach ache) (very little<br /><br>* a lot)..<br /><br>- The percentage of patients with either CFRD or IGT according to results of<br /><br>either AATT of OGTT.<br /><br>- The optimal cut-off levels for the AATT using OGTT as a reference standard</p><br>